Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238744 | 0.87 | CHRM5 (0.39) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| Hydrochloric Acid SCHEMBL3230095 | 0.85 | CHRM5 (0.38) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL25856483 | 0.82 | OPRL1 (0.39) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL21947721 | 0.80 | ACHE (0.40) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL27425161 | 0.80 | ACHE (0.45) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL25630859 | 0.78 | OPRL1 (0.43) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL680627 | 0.78 | ACHE (0.47) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL29307076 | 0.75 | CHRM5 (0.38) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL25605614 | 0.74 | OPRL1 (0.39) | OPRL1OPRM1OPRK1OPRD1ACHE | |
| SCHEMBL21450690 | 0.73 | CHRM5 (0.59) | OPRL1OPRM1OPRK1OPRD1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131167-A1 | COMPOUND FOR INHIBITING AND DEGRADING IRAK4, AND PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 海思科医药集团股份有限公司 | 2023-07-13 | — | — | WO | disclosed |